Elicera Therapeutics: All eyes on upcoming data - Redeye
Redeye provides a brief summary of Elicera’s Q1'25 report. With new clinical data from the CARMA study expected next week, we will hold off on providing an updated analysis until the results are available.
ANNONS
Redeye provides a brief summary of Elicera’s Q1'25 report. With new clinical data from the CARMA study expected next week, we will hold off on providing an updated analysis until the results are available.
